- Home
- BIVI vs VRCA Comparison
BIVI vs VRCA Comparison
Compare BIVI & VRCA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BIVI
- VRCA
- Stock Information
- Founded
- BIVI 2013
- VRCA 2013
- Country
- BIVI United States
- VRCA United States
- Employees
- BIVI 14
- VRCA N/A
- Industry
- BIVI Biotechnology: Pharmaceutical Preparations
- VRCA Biotechnology: Pharmaceutical Preparations
- Sector
- BIVI Health Care
- VRCA Health Care
- Exchange
- BIVI Nasdaq
- VRCA Nasdaq
- Market Cap
- BIVI 18.8M
- VRCA 58.0M
- IPO Year
- BIVI N/A
- VRCA 2018
- Fundamental
- Price
- BIVI $1.02
- VRCA $0.59
- Analyst Decision
- BIVI Strong Buy
- VRCA Hold
- Analyst Count
- BIVI 1
- VRCA 5
- Target Price
- BIVI $30.00
- VRCA $6.00
- AVG Volume (30 Days)
- BIVI 297.1K
- VRCA 341.5K
- Earning Date
- BIVI 05-13-2025
- VRCA 03-11-2025
- Dividend Yield
- BIVI N/A
- VRCA N/A
- EPS Growth
- BIVI N/A
- VRCA N/A
- EPS
- BIVI N/A
- VRCA N/A
- Revenue
- BIVI N/A
- VRCA $7,566,000.00
- Revenue This Year
- BIVI N/A
- VRCA $93.38
- Revenue Next Year
- BIVI N/A
- VRCA $127.27
- P/E Ratio
- BIVI N/A
- VRCA N/A
- Revenue Growth
- BIVI N/A
- VRCA 47.66
- 52 Week Low
- BIVI $0.99
- VRCA $0.54
- 52 Week High
- BIVI $7.50
- VRCA $11.41
- Technical
- Relative Strength Index (RSI)
- BIVI 23.10
- VRCA 39.26
- Support Level
- BIVI $1.09
- VRCA $0.54
- Resistance Level
- BIVI $1.24
- VRCA $0.68
- Average True Range (ATR)
- BIVI 0.10
- VRCA 0.07
- MACD
- BIVI -0.01
- VRCA -0.00
- Stochastic Oscillator
- BIVI 6.67
- VRCA 22.81
About BIVI BioVie Inc.
BioVie Inc is a clinical-stage company developing drug therapies to treat chronic debilitating conditions including liver disease and neurological and neuro-degenerative disorders and certain cancers. The Company is conducting a potentially pivotal Phase 3 randomized, double-blind, placebo-controlled, parallel-group, multicenter study to evaluate NE3107 in patients who have mild to moderate Alzheimer's disease. BIV201 has the potential to improve the health of thousands of patients suffering from life-threatening complications of liver cirrhosis due to hepatitis, non-alcoholic steatohepatitis and alcoholism.
About VRCA Verrica Pharmaceuticals Inc.
Verrica Pharmaceuticals Inc is a dermatology therapeutics company engaged in the development and commercialization of novel treatments that provide a meaningful benefit for people living with skin diseases. Its product candidate, VP-102, is developed for the treatment of molluscum contagiosum, or molluscum, a contagious and pediatric viral skin disease, and common warts.